RESULTS	For the primary outcome measure , significant superiority of EGb 761 over placebo was demonstrated in the intention-to-treat analysis data set after 4 , 8 and 12 weeks of out-patient treatment ( p < 0.05 , 1-tailed ) , although the absolute treatment group difference was moderate .\